Serine/threonine protein kinase Sgk1, also known as serum and glucocorticoid-regulated kinase 1, is an enzyme encoded by the SGK1 gene in humans. SGK1 belongs to the serine/threonine kinase subfamily and is under acute transcriptional control by a variety of stimuli including serum and glucocorticoids. This kinase is activated by insulin and growth factors through phosphatidylinositol 3-kinase, phosphoinositide-dependent kinase PDK1 and mammalian rapamycin mTORC2 targets. In the past few years, there has been increasing evidence that SGK1 expression is regulated in discrete developmental stages and pathological conditions (such as hypertension, diabetic neuropathy, ischemia, trauma, and neurodegenerative diseases).
Neurodegenerative diseases such as Alzheimer's disease are the main cause of dementia in elderly patients, and these diseases still lack effective treatments. According to reports, inhibiting certain enzymes related to abnormal gene transcription can restore Alzheimer’s-related memory loss. This discovery offers hope for the development of new treatments for Alzheimer’s disease. The top-ranked gene is SGK1, which encodes serum and glucocorticoid-regulated kinase 1, and SGK1 is also significantly elevated in the prefrontal cortex of patients with Alzheimer's disease. The researchers gave mice a specific inhibitor of SGK1 and observed that the level of hyperphosphorylated tau protein was significantly reduced, the function of glutamatergic synapses in the prefrontal cortex was restored, and the memory impairment of AD mice was also improved. [1]
Our Services
- Design SGK1 Targeting inhibitors based on the similarity with natural ligands.
- Structural optimization and energy minimization of the designed inhibitors.
- Use high-throughput and other methods to screen compounds.
- Provide SGK1 Targeting molecular docking and molecular dynamics simulation services.
- Choose the appropriate simulated solvent for you, limit the force and other conditions.
- Provide full-atom or coarse-grained dynamics simulation services.
- Provide system stability testing services.
- Provide energy analysis and energy decomposition services.
- Use statistical techniques to process data and analyze results.
Provided by Clients
Please inform us of the details about your SGK1 targeting research project after signing a non-disclosure agreement, which can be specific to the force field of molecular dynamics simulation, and the result analysis requirements.
Deliverables
- Design results of SGK1 targeting inhibitors
- Docking score
- Comparison with natural ligand docking score
- Compound optimized initial structure
- Molecular dynamics simulation of initial structure
- Molecular dynamics simulation raw data
- Result analysis and other data, picture analysis report, etc.
Our advantages
- CD ComputaBio has successfully solved multiple target service solutions, providing different solutions for drug discovery.
- We will provide one-stop professional design and validation services.
- We have strict quality control at every step of the target service to ensure that our customers receive high-quality data.
If you want to know more about SGK1 targeting services provided by CD ComputaBio, please contact us at any time.
Reference:
-
Cao Q, Wang W, Williams J B, et al. Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease. Science Advances, 2020, 6(50).
* For Research Use Only.
